A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

[1]  M. Aapro,et al.  Practical guidance for the management of aromatase inhibitor-associated bone loss. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Dowsett,et al.  Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Neven,et al.  Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.

[4]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.

[5]  R. Eastell,et al.  Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. , 2007, European journal of cancer.

[6]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[8]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[10]  J. Cuzick,et al.  Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[12]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[13]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[14]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ego Seeman,et al.  Pathogenesis of bone fragility in women and men , 2002, The Lancet.

[16]  B. Riggs,et al.  Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? , 2000, Bone.

[17]  K. Horwitz.  Bringing estrogen receptors under control , 1999, Breast Cancer Research.

[18]  C. Osborne,et al.  Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. , 1999, Endocrine-related cancer.

[19]  P. Bruzzi.  Tamoxifen for the prevention of breast cancer , 1998, BMJ.

[20]  P. Hietanen,et al.  Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.

[21]  P. Lønning,et al.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.

[22]  T. Powles,et al.  The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  I. Reid,et al.  The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.

[24]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Glass,et al.  Biochemical markers. , 1981, Science.